RE: I think it's about25 Jun 2025 13:14
Big month July23 Jun 2025 22:16
Nutts academic research seems golden so far and we far from having an absence of solid intellectual property.
In-vitro screening for SERT, DAT, and NET release - Evotec appointed by Awakn to lead key preclinical testing.
To ensure the highest standard of preclinical validation, Awakn has appointed Evotec, a globally recognised leader in drug discovery and development, to conduct in-vitro screening for SERT, DAT, and NET release activity.
Evotec brings world-class expertise in:
ยท Neurotransmitter pharmacology
ยท High-throughput screening
ยท Precision drug discovery
Evotec's analysis will provide critical insights into the candidates' ability to modulate neurotransmitter release, a key mechanism underpinning AWKN-SDN-14's therapeutic potential.
This in-vitro testing phase, which builds on the positive animal testing results, is expected to be completed by the end of July 2025, aligning with the revised Programme timelin